BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842-1847. [PMID: 8247035 DOI: 10.1056/nejm199312163292503] [Cited by in Crossref: 811] [Cited by in F6Publishing: 105] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010;16:4377-93. [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs. 2002;4:361-369. [PMID: 12038872 DOI: 10.2165/00128072-200204060-00003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
4 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
5 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
6 Ishigami M, Ogura Y, Hirooka Y, Goto H. Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2015; 21(36): 10290-10298 [PMID: 26420956 DOI: 10.3748/wjg.v21.i36.10290] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
7 Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol 2021; 13(3): 291-299 [PMID: 33815673 DOI: 10.4254/wjh.v13.i3.291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol. 2011;2011:918017. [PMID: 21994876 DOI: 10.4061/2011/918017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
9 Dehghani SM, Taghavi SA, Geramizadeh B, Nikeghbalian S, Derakhshan N, Malekpour A, Malek-Hosseini SA. Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature. Hepat Mon. 2013;13:e6609. [PMID: 23483668 DOI: 10.5812/hepatmon.6609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
10 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
11 Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, Li YL, Wang T. Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One 2012;7:e51512. [PMID: 23272112 DOI: 10.1371/journal.pone.0051512] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
12 Lu Y, Lin Y, Zheng Z, Tang X, Lin J, Liu X, Liu M, Chen G, Qiu S, Zhou T, Lin Y, Feng S. Label free hepatitis B detection based on serum derivative surface enhanced Raman spectroscopy combined with multivariate analysis. Biomed Opt Express 2018;9:4755-66. [PMID: 30319900 DOI: 10.1364/BOE.9.004755] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
13 Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, Gane EJ, Angus PW. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation. JGH Open 2018;2:288-94. [PMID: 30619939 DOI: 10.1002/jgh3.12086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Moucari R, Francoz C, Lada O, Abdel Razek W, Marcellin P, Valla D, Belghiti J, Durand F. Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy. Liver Int 2009;29:775-6. [PMID: 19422074 DOI: 10.1111/j.1478-3231.2008.01944.x] [Reference Citation Analysis]
15 Ahn J, Cohen SM. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. Hepat Mon. 2011;11:638-645. [PMID: 22140388 DOI: 10.5812/kowsar.1735143x.1010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
16 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
17 Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J, Fong TL. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation. Dig Dis Sci 2015;60:2807-12. [PMID: 25939541 DOI: 10.1007/s10620-015-3671-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
18 Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG. Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study. World J Gastroenterol 2015; 21(2): 584-592 [PMID: 25593480 DOI: 10.3748/wjg.v21.i2.584] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
19 Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut. 1998;42:744-749. [PMID: 9659174 DOI: 10.1136/gut.42.5.744] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
20 Roche B, Roque-Afonso AM, Nevens F, Samuel D. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation. 2015;99:1321-1334. [PMID: 26038873 DOI: 10.1097/tp.0000000000000777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
21 Mas A. Contributions to our understanding of fulminant hepatitis from the Liver ICU of Hospital Clínic Barcelona: Historical review. Gastroenterol Hepatol 2017;40:649.e1-6. [PMID: 28728832 DOI: 10.1016/j.gastrohep.2017.06.003] [Reference Citation Analysis]
22 Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 2012;8:e1002895. [PMID: 22952447 DOI: 10.1371/journal.ppat.1002895] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 11.5] [Reference Citation Analysis]
23 Castells L. [Viral hepatitides infections in transplant recipients]. Enferm Infecc Microbiol Clin 2006;24:118-28. [PMID: 16545319 DOI: 10.1157/13085018] [Reference Citation Analysis]
24 Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K, Koga H, Takao Y. Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci. 2008;53:2999-3006. [PMID: 18618250 DOI: 10.1007/s10620-008-0384-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med 2015;5:a021543. [PMID: 26253093 DOI: 10.1101/cshperspect.a021543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
26 Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017;31:311-320. [PMID: 28774413 DOI: 10.1016/j.bpg.2017.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
27 Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci. 2005;20:821-828. [PMID: 16224157 DOI: 10.3346/jkms.2005.20.5.821] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lu SC, Jiang T, Lai W, Liu Y, Zhang J, Zeng DB, Li CY, Wang ML, Lin DD, Zhu Y. Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease. J Immunol Res. 2014;2014:764234. [PMID: 25759834 DOI: 10.1155/2014/764234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
29 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010; 16(35): 4377-4393 [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
30 Vargas HE, Rakela J. Impact of hepatitis B and hepatitis C on solid organ transplantation: . Current Opinion in Organ Transplantation 2002;7:325-31. [DOI: 10.1097/00075200-200212000-00005] [Reference Citation Analysis]
31 Schutz SM, Stevenson W. Reply. Annals of Saudi Medicine 1995;15:669-70. [DOI: 10.5144/0256-4947.1995.669a] [Reference Citation Analysis]
32 Schemmer P, Burra P, Hu RH, Hüber CM, Loinaz C, Machida K, Vogel A, Samuel D. State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. Liver Int 2021. [PMID: 34846790 DOI: 10.1111/liv.15124] [Reference Citation Analysis]
33 Al-hamoudi W, Elsiesy H, Bendahmash A, Al-masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol 2015; 21(26): 8140-8147 [PMID: 26185387 DOI: 10.3748/wjg.v21.i26.8140] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
34 Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol 2015; 7(10): 1421-1426 [PMID: 26052387 DOI: 10.4254/wjh.v7.i10.1421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
35 Roche B, Samuel D. Hepatitis: viral load predicts HBV recurrence after liver transplant. Nat Rev Gastroenterol Hepatol. 2010;7:657-658. [PMID: 21124520 DOI: 10.1038/nrgastro.2010.165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
36 Carson KL, Hunt CM. Medical problems occurring after orthotopic liver transplantation. Dig Dis Sci 1997;42:1666-74. [PMID: 9286232 DOI: 10.1023/a:1018853213442] [Cited by in Crossref: 23] [Article Influence: 0.9] [Reference Citation Analysis]
37 Ye J, Shao H, Perez DR. Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy 2012;4:175-86. [PMID: 22339460 DOI: 10.2217/imt.11.167] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
38 Ichai P, Samuel D. Management of Fulminant Hepatitis B. Curr Infect Dis Rep 2019;21:25. [PMID: 31165271 DOI: 10.1007/s11908-019-0682-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Figueiredo RS, Thakkar RG, Ainley PR, Wilson CH. Review of abdominal solid organ transplantation in Jehovah’s Witness patients. World J Transplant 2019; 9(5): 94-102 [PMID: 31598468 DOI: 10.5500/wjt.v9.i5.94] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Ballarin R, Cucchetti A, Russo FP, Magistri P, Cescon M, Cillo U, Burra P, Pinna AD, Di Benedetto F. Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World J Gastroenterol 2017; 23(12): 2095-2105 [PMID: 28405138 DOI: 10.3748/wjg.v23.i12.2095] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155 [PMID: 25339803 DOI: 10.3748/wjg.v20.i39.14142] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
42 Lok AS. Progress in hepatitis B: a 30-year journey through three continents. Hepatology 2014;60:4-11. [PMID: 24619499 DOI: 10.1002/hep.27120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
43 McCaughan GW. Prevention of post liver transplant HBV recurrence. Hepatol Int. 2011; Aug 10. [Epub ahead of print]. [PMID: 22020819 DOI: 10.1007/s12072-011-9293-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
44 Varghese J, Sachan D, Reddy MS, Cherian T, Jothimani D, Venugopal K, Arikichenin O, Perumalla R, Narasimhan G, Shanmugam V. Hepatitis B immunoglobulin prophylaxis after liver transplantation: experience in a tertiary transplant centre. J Clin Exp Hepatol. 2014;4:209-213. [PMID: 25755562 DOI: 10.1016/j.jceh.2014.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Lai CL, Yuen MF. Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med. 2015;5:pii a021527. [PMID: 26033083 DOI: 10.1101/cshperspect.a021527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
46 Gao JL, Shi XL. Perioperative management in liver transplantation for acute liver failure. Shijie Huaren Xiaohua Zazhi 2013; 21(36): 4104-4109 [DOI: 10.11569/wcjd.v21.i36.4104] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci. 2010;55:505-509. [PMID: 19802696 DOI: 10.1007/s10620-009-0999-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
48 Yi NJ, Lee KW, Kong SY, Park KU, Lee KB, Hong G, Han SS, Park SJ, Suh KS. Outcome of various treatments for posttransplant hepatitis B virus recurrence. World J Surg. 2013;37:812-819. [PMID: 23344522 DOI: 10.1007/s00268-013-1914-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
49 Dodson SF. Monotherapy Versus Combination Therapy in the Prevention of Hepatitis B in Liver Transplant Recipients: . BioDrugs 2000;14:205-9. [DOI: 10.2165/00063030-200014040-00001] [Reference Citation Analysis]
50 Bihl F, Russmann S, Gurtner V, Di Giammarino L, Pizzi-Bosman L, Michel M, Cerny A, Hadengue A, Majno P, Giostra E, Castelli D, Mentha G. Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. BMC Gastroenterol 2010;10:71. [PMID: 20598161 DOI: 10.1186/1471-230X-10-71] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
51 Terrault NA, Wright TL. Hepatitis B virus infection and liver transplantation. Gut. 1997;40:568-571. [PMID: 9203930 DOI: 10.1136/gut.40.5.568] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
52 Fan ST. Liver transplantation in Asia: Problems and practice. J Gastroenterol Hepatol 1998;13:S308-10. [PMID: 28976673 DOI: 10.1111/j.1440-1746.1998.tb01899.x] [Reference Citation Analysis]
53 Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, Ball JK. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 2012;86:2739-49. [PMID: 22171278 DOI: 10.1128/JVI.06492-11] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
54 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014; 20(43): 16053-16061 [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
55 Cerino A, Bremer CM, Glebe D, Mondelli MU. A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity. PLoS One. 2015;10:e0125704. [PMID: 25923526 DOI: 10.1371/journal.pone.0125704] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
56 Mutimer D. Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? Gut 1999;45:475-6. [PMID: 10486345 DOI: 10.1136/gut.45.4.475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
57 Jothimani D, Venugopal R, Vij M, Rela M. Post liver transplant recurrent and de novo viral infections. Best Pract Res Clin Gastroenterol. 2020;46-47:101689. [PMID: 33158469 DOI: 10.1016/j.bpg.2020.101689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
58 Xia NX, Fu ZR, Qiu BA, Wang ZX, Li XX, Bai G, Yang YX, Wang K. Low-dose intra-muscular hepatitis B immunoglobulin combined with lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Shijie Huaren Xiaohua Zazhi 2006; 14(13): 1288-1293 [DOI: 10.11569/wcjd.v14.i13.1288] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
59 Ho CM, Lee PH, Cheng WT, Hu RH, Wu YM, Ho MC. Succinct guide to liver transplantation for medical students. Ann Med Surg (Lond) 2016;12:47-53. [PMID: 27895907 DOI: 10.1016/j.amsu.2016.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8. [PMID: 16600049 DOI: 10.1186/1476-0711-5-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
61 Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol. 2003;77:8882-8892. [PMID: 12885906 DOI: 10.1128/jvi.77.16.8882-8892.2003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
62 Buti M, Castells L. Prevention and treatment of hepatitis B virus recurrence after liver transplantation: . Current Opinion in Organ Transplantation 2006;11:589-93. [DOI: 10.1097/mot.0b013e3280102b22] [Reference Citation Analysis]
63 Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Emre S, Soldevila-Pico C, Reddy KR, Ishitani MB. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10:1823-1833. [PMID: 20346062 DOI: 10.1111/j.1600-6143.2010.03046.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
64 Vatansever S, Farajov R, Yılmaz HC, Zeytunlu M, Kılıç M. The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence. Turk J Med Sci 2019;49:1019-24. [PMID: 31385669 DOI: 10.3906/sag-1808-86] [Reference Citation Analysis]
65 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
66 Meshikhes AW. An overview of orthotopic liver transplantation. Ann Saudi Med 1995;15:669. [PMID: 17589040 DOI: 10.5144/0256-4947.1995.669] [Reference Citation Analysis]
67 Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, Fan ST, Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-81. [PMID: 11176135 DOI: 10.1097/00000658-200102000-00018] [Cited by in Crossref: 107] [Cited by in F6Publishing: 92] [Article Influence: 5.1] [Reference Citation Analysis]
68 Yang G, Ou M, Chen H, Guo C, Chen J, Lin H, Tang D, Xue W, Li W, Sui W, Dai Y. Characteristic analysis of TCR β-chain CDR3 repertoire for pre- and post-liver transplantation. Oncotarget 2018;9:34506-19. [PMID: 30349645 DOI: 10.18632/oncotarget.26138] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
69 Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S, Vesin B, Lorin V, Hieu T, Stauffer A, Fiquet O, Dimitrov JD, Michel ML, Ungeheuer MN, Sureau C, Pol S, Di Santo JP, Strick-Marchand H, Pelletier N, Mouquet H. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. J Exp Med 2020;217:e20200840. [PMID: 32579155 DOI: 10.1084/jem.20200840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
70 Weakley T, Rajender Reddy K. Hepatitis B. Curr Treat Options Gastroenterol 1999;2:463-72. [PMID: 11097730 DOI: 10.1007/s11938-999-0050-1] [Reference Citation Analysis]
71 Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21(3): 829-835 [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
72 Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000;13:602-14. [PMID: 11023960 DOI: 10.1128/CMR.13.4.602] [Cited by in Crossref: 166] [Cited by in F6Publishing: 1] [Article Influence: 7.5] [Reference Citation Analysis]
73 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
74 Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol 2018;9:79-84. [PMID: 29484165 DOI: 10.1136/flgastro-2016-100768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
75 Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
76 Onoe T, Tahara H, Tanaka Y, Ohdan H. Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol 2016; 22(1): 165-175 [PMID: 26755868 DOI: 10.3748/wjg.v22.i1.165] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
77 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2432-2434 [DOI: 10.11569/wcjd.v12.i10.2432] [Reference Citation Analysis]
78 Tan CK. Liver transplantation: late complications. Transplant Proc 2000;32:1517-8. [PMID: 11119814 DOI: 10.1016/s0041-1345(00)01333-6] [Reference Citation Analysis]
79 Ferrarese A, Zanetto A, Gambato M, Bortoluzzi I, Nadal E, Germani G, Senzolo M, Burra P, Russo FP. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol 2016; 22(4): 1570-1581 [PMID: 26819523 DOI: 10.3748/wjg.v22.i4.1570] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
80 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018; 10(3): 352-370 [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
81 Targhetta S, Villamil F, Inturri P, Pontisso P, Fagiuoli S, Cillo U, Cecchetto A, Gianni S, Naccarato R, Burra P. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J Gastroenterol 2006; 12(11): 1706-1712 [PMID: 16586538 DOI: 10.3748/wjg.v12.i11.1706] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
82 Shukla A, Vadeyar H, Rela M, Shah S. Liver Transplantation: East versus West. J Clin Exp Hepatol 2013;3:243-53. [PMID: 25755506 DOI: 10.1016/j.jceh.2013.08.004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
83 Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol 2016; 22(14): 3803-3812 [PMID: 27076765 DOI: 10.3748/wjg.v22.i14.3803] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
84 Chou HS, Cheng CH, Hung HC, Lee JC, Wang YC, Wu TH, Lee CF, Wu TJ, Chan KM, Lee WC. Significance of Hepatitis B Recurrence in Liver Transplantation Recipients. Biomed Res Int 2020;2020:2489526. [PMID: 32934957 DOI: 10.1155/2020/2489526] [Reference Citation Analysis]
85 Wang K, Zhu ZJ, Zheng H, Deng YL, Pan C, Sun LY, Shen ZY. Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases. Hepatol Res 2012;42:280-7. [PMID: 22176205 DOI: 10.1111/j.1872-034X.2011.00926.x] [Reference Citation Analysis]
86 Choi HJ, Kim DG, Kim SI, Wang HJ, Joh JW, Suh KS, Kim SH. A Multicenter Phase III Study to Evaluate the Efficacy and Safety of Hepabulin, a New Hepatitis B Immunoglobulin, in Liver Transplantation Recipients with Hepatitis B. Ann Transplant 2017;22:740-8. [PMID: 29229898 DOI: 10.12659/aot.905898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Uetsuji S, Komada H, Kwon AH, Kamiyama Y, Uedono Y, Tanaka T. Assessing the eligibility for liver transplantation of patients with fulminant hepatitis. Surg Today 1997;27:186-8. [PMID: 9018002 DOI: 10.1007/BF02385914] [Reference Citation Analysis]
88 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6:696-700. [PMID: 18456569 DOI: 10.1016/j.cgh.2008.02.055] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
90 Ajayi T, Luu H, Saberi B, Hamilton JP, Konduk BT, Özşeker B, Al Khalloufi K, Pustavoitau A, Philosophe B, Cameron AM, Gürakar A. Role of nucleoside/nucleotide analogues and low-dose hepatitis B immune globülin in prophylaxis of hepatitis B recurrence among cadaveric liver transplant recipients. Turk J Gastroenterol 2018;29:61-6. [PMID: 29391309 DOI: 10.5152/tjg.2018.17595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg. 1998;227:841-850. [PMID: 9637547 DOI: 10.1097/00000658-199806000-00007] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 5.0] [Reference Citation Analysis]
92 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
93 Welker MW, Zeuzem S. Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). Visc Med 2016;32:105-9. [PMID: 27413727 DOI: 10.1159/000445152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
94 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol. 2013;48:1373-1383. [PMID: 23435670 DOI: 10.1007/s00535-013-0763-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
96 Maiwall R, Kumar M. Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol 2016;4:54-65. [PMID: 27047773 DOI: 10.14218/JCTH.2015.00041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
97 Hammami MB, Kohli R, Woreta T, Sulkowski MS, Hamilton JP, Toman L, Saberi B, Laurin J, Wang JG, Philosophe B, Cameron AM, Gurakar A. Hepatitis B Virus/Hepatitis D Virus-Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid-Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. ACG Case Rep J 2021;8:e00582. [PMID: 34549060 DOI: 10.14309/crj.0000000000000582] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
99 Graziadei I. [Intensive care treatment before and after liver transplantation]. Med Klin Intensivmed Notfmed 2014;109:411-7. [PMID: 25142222 DOI: 10.1007/s00063-014-0364-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Nasir M, Wu GY. Prevention of HBV Recurrence after Liver Transplant: A Review. J Clin Transl Hepatol 2020;8:150-60. [PMID: 32832395 DOI: 10.14218/JCTH.2020.00003] [Reference Citation Analysis]
101 Kushner T, Da BL, Chan A, Dieterich D, Sigel K, Saberi B. Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era. Transplant Direct 2022;8:e1253. [PMID: 34957333 DOI: 10.1097/TXD.0000000000001253] [Reference Citation Analysis]
102 Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon. 2012;12:168-176. [PMID: 22550524 DOI: 10.5812/hepatmon.832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
103 Herrero JI, Quiroga J, Sangro B, Sola I, Riezu-Boj JI, Pardo F, Prieto J. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Dig Dis Sci 1998;43:1186-9. [PMID: 9635605 DOI: 10.1023/a:1018887203545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
104 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
105 Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, Hirohata S, Tatsukawa M, Kawai D, Shiraha H. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int. 2011;5:918-926. [PMID: 21484119 DOI: 10.1007/s12072-011-9265-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
106 Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, Peppelenbosch MP, Liu J, Pan Q. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020;221:1677-1687. [PMID: 31778167 DOI: 10.1093/infdis/jiz633] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 39.0] [Reference Citation Analysis]
107 Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N, Cantarovich M, Cleland P, Metrakos P, Meakins JL. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997;226:356-65; discussion 365-8. [PMID: 9339942 DOI: 10.1097/00000658-199709000-00015] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis]
108 Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006;80:2654-64. [PMID: 16501075 DOI: 10.1128/JVI.80.6.2654-2664.2006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
109 Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000;13:602-14. [PMID: 11023960 DOI: 10.1128/CMR.13.4.602] [Cited by in Crossref: 88] [Cited by in F6Publishing: 112] [Article Influence: 4.0] [Reference Citation Analysis]
110 Takaki A, Yasunaka T, Yagi T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci 2015;16:17494-513. [PMID: 26263973 DOI: 10.3390/ijms160817494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
111 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
112 John S, Andersson KL, Kotton CN, Hertl M, Markmann JF, Cosimi AB, Chung RT. Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol 2013;6:309-19. [PMID: 23814610 DOI: 10.1177/1756283X13487942] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
113 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
114 Montalbano M, Neff GW. Management of recurrent viral hepatitis B and C after liver transplantation. Curr Gastroenterol Rep 2006;8:60-6. [PMID: 16510036 DOI: 10.1007/s11894-006-0065-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Sapiano MRP, Jones JM, Bowman J, Levi ME, Basavaraju SV. Impact of US Public Health Service increased risk deceased donor designation on organ utilization. Am J Transplant 2019;19:2560-9. [PMID: 30959569 DOI: 10.1111/ajt.15388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
116 Yoshida EM, Méndez-sánchez N. Hepatology Highlights. Annals of Hepatology 2010;9:117-9. [DOI: 10.1016/s1665-2681(19)31649-7] [Reference Citation Analysis]
117 Takaki A, Yagi T, Yamamoto K. Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res. 2015;45:38-47. [PMID: 24905970 DOI: 10.1111/hepr.12368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
118 Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg. 2002;235:611-619; discussion 619-620. [PMID: 11981206 DOI: 10.1097/00000658-200205000-00002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
119 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Reference Citation Analysis]
120 Walsh K, Alexander GJ. Update on chronic viral hepatitis. Postgrad Med J 2001;77:498-505. [PMID: 11470928 DOI: 10.1136/pmj.77.910.498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
121 Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-9. [PMID: 11772974 DOI: 10.1136/gut.50.1.95] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 4.7] [Reference Citation Analysis]
122 Tang YM, Chen MH, Chen GH, Cai CJ, He XS, Lu MG, Bao WM. Kinetics of phytohemaglutinin-induced IFN-γ and TNF-α expression in peripheral blood mononuclear cells from patients with chronic hepatitis B after liver transplantation. World J Gastroenterol 2005; 11(29): 4574-4578 [PMID: 16052691 DOI: 10.3748/wjg.v11.i29.4574] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
123 Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current Status of Therapy and Future Therapies. Gastroenterol Clin North Am 2020;49:215-38. [PMID: 32389360 DOI: 10.1016/j.gtc.2020.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
124 Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C, Rando-Muñoz FJ. Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol 2015; 21(42): 12083-12090 [PMID: 26576093 DOI: 10.3748/wjg.v21.i42.12083] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]